➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Medtronic
Harvard Business School
Johnson and Johnson
Baxter

Last Updated: June 15, 2021

DrugPatentWatch Database Preview

LANTHEUS MEDCL Company Profile


Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for LANTHEUS MEDCL, and what generic alternatives to LANTHEUS MEDCL drugs are available?

LANTHEUS MEDCL has nine approved drugs.

There are five US patents protecting LANTHEUS MEDCL drugs.

There are forty-two patent family members on LANTHEUS MEDCL drugs in fourteen countries and eight supplementary protection certificates in five countries.

Summary for LANTHEUS MEDCL
International Patents:42
US Patents:5
Tradenames:10
Ingredients:8
NDAs:9

Drugs and US Patents for LANTHEUS MEDCL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes 9,789,210   Get Started Free   Get Started Free
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes 10,583,208   Get Started Free   Get Started Free
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes 10,583,207   Get Started Free   Get Started Free
Lantheus Medcl THALLOUS CHLORIDE TL 201 thallous chloride tl-201 INJECTABLE;INJECTION 017806-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LANTHEUS MEDCL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 6,773,696   Get Started Free
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 5,769,080   Get Started Free
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 6,676,929   Get Started Free
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 5,362,475   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for LANTHEUS MEDCL Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0806968 07C0028 France   Get Started Free PRODUCT NAME: GADOFOSVESET TRISODIQUE; REGISTRATION NO/DATE: EU/1/05/313/001-009 20051003
0806968 PA2007003 Lithuania   Get Started Free PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005
1178838 300736 Netherlands   Get Started Free PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
0712293 SPC/GB07/031 United Kingdom   Get Started Free PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Harvard Business School
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.